Connect Biopharma Net Worth
Connect Biopharma Net Worth Breakdown | CNTB |
Connect Biopharma Net Worth Analysis
Connect Biopharma's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Connect Biopharma's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Connect Biopharma's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Connect Biopharma's net worth analysis. One common approach is to calculate Connect Biopharma's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Connect Biopharma's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Connect Biopharma's net worth. This approach calculates the present value of Connect Biopharma's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Connect Biopharma's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Connect Biopharma's net worth. This involves comparing Connect Biopharma's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Connect Biopharma's net worth relative to its peers.
Enterprise Value |
|
To determine if Connect Biopharma is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Connect Biopharma's net worth research are outlined below:
| Connect Biopharma had very high historical volatility over the last 90 days | |
| Connect Biopharma has some characteristics of a very speculative penny stock | |
| Net Loss for the year was (59.38 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Connect Biopharma Holdings currently holds about 1.28 B in cash with (47.93 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 23.26, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Connect Biopharma has a frail financial position based on the latest SEC disclosures | |
| Roughly 41.0% of the company shares are held by company insiders | |
| Latest headline from simplywall.st: US Penny Stocks To Monitor In November 2024 |
Connect Biopharma uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Connect Biopharma Holdings. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Connect Biopharma's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 9th of April 2024 Upcoming Quarterly Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 9th of April 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know Connect Biopharma's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Connect Biopharma is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Connect Biopharma Holdings backward and forwards among themselves. Connect Biopharma's institutional investor refers to the entity that pools money to purchase Connect Biopharma's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Qube Research & Technologies | 2024-06-30 | 46.0 | Fidelity Management And Research Company | 2024-06-30 | 0.0 | Two Sigma Investments Llc | 2024-06-30 | 0.0 | Bml Capital Management Llc | 2024-09-30 | 2.1 M | Ubs O'connor Llc | 2024-09-30 | 510.7 K | Renaissance Technologies Corp | 2024-09-30 | 175.5 K | Blackrock Inc | 2024-06-30 | 103.9 K | Keudell/morrison Wealth Management | 2024-09-30 | 33.5 K | Geode Capital Management, Llc | 2024-09-30 | 28 K | Commonwealth Equity Services Inc | 2024-06-30 | 20 K | Royal Bank Of Canada | 2024-06-30 | 12.7 K |
Follow Connect Biopharma's market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 54.04 M.Market Cap |
|
Project Connect Biopharma's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.47) | (0.50) | |
| Return On Capital Employed | (0.61) | (0.64) | |
| Return On Assets | (0.47) | (0.50) | |
| Return On Equity | (0.59) | (0.56) |
When accessing Connect Biopharma's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Connect Biopharma's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Connect Biopharma's profitability and make more informed investment decisions.
Please note, the presentation of Connect Biopharma's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Connect Biopharma's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Connect Biopharma's management manipulating its earnings.
Evaluate Connect Biopharma's management efficiency
Connect Biopharma has return on total asset (ROA) of (0.1213) % which means that it has lost $0.1213 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.1792) %, meaning that it created substantial loss on money invested by shareholders. Connect Biopharma's management efficiency ratios could be used to measure how well Connect Biopharma manages its routine affairs as well as how well it operates its assets and liabilities. As of November 26, 2024, Return On Tangible Assets is expected to decline to -0.5. In addition to that, Return On Capital Employed is expected to decline to -0.64. At present, Connect Biopharma's Net Tangible Assets are projected to increase significantly based on the last few years of reporting. The current year's Total Current Assets is expected to grow to about 203.4 M, whereas Other Assets are forecasted to decline to 0.00.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 1.83 | 1.00 | |
| Tangible Book Value Per Share | 1.83 | 0.99 | |
| Enterprise Value Over EBITDA | 0.69 | 0.73 | |
| Price Book Value Ratio | 0.64 | 0.68 | |
| Enterprise Value Multiple | 0.69 | 0.73 | |
| Price Fair Value | 0.64 | 0.68 | |
| Enterprise Value | -46.6 M | -44.3 M |
Understanding the operational decisions made by Connect Biopharma management offers insights into its financial robustness. This evaluation is crucial for assessing the stock's investment potential.
Revenue 24.1 M | Revenue Per Share 0.438 | Return On Equity (0.18) |
Connect Biopharma Earnings per Share Projection vs Actual
Connect Biopharma Corporate Management
| Steven Chan | Chief Officer | Profile | |
| Raul Collazo | VP Affairs | Profile | |
| Lei Sun | VP CMC | Profile | |
| Jiang JD | General Officer | Profile |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Connect Biopharma Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Share Portfolio module to track or share privately all of your investments from the convenience of any device.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Connect Biopharma. If investors know Connect will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Connect Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.39) | Revenue Per Share 0.438 | Return On Assets (0.12) | Return On Equity (0.18) |
The market value of Connect Biopharma is measured differently than its book value, which is the value of Connect that is recorded on the company's balance sheet. Investors also form their own opinion of Connect Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Connect Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Connect Biopharma's market value can be influenced by many factors that don't directly affect Connect Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Connect Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Connect Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Connect Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.